Skip to content

Study · Not a test of the peptide alone · 2010

2 results

Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.

Doedens L, Opperer F, Cai M, Beck JG, Dedek M, Palmer E, Hruby VJ, Kessler H

Journal of the American Chemical Society1 Jun 2010Cited by 82 (Europe PMC)

PMID20496895 (opens in a new tab)PMCIDPMC2895553 (opens in a new tab)DOI10.1021/ja101428m (opens in a new tab)PepBankPUB-20496895
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 01LabNot a test of Melanotan II aloneIn vitro (cells)Activity measurement

    Selectivity of N-methylated MT-II derivatives improved with every added N-methyl group, giving several selective and potent hMC1R agonists.

    In plain wordsIn lab tests, chemically modified versions of MT-II became more selective for one receptor type with each added methyl group.

    Peptide
    Melanotan II
    Outcome
    IncreasehMC1R selectivity and agonist potency of N-methylated MT-II derivatives
    Study

    n: not reported in source

    Melanocortin receptor subtypes 1, 3, 4 and 5
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    It turned out that selectivity is improved with every introduced N-methyl group, resulting in several N-methylated selective and potent agonists for the hMC1R.
    1 context sentence
    Summary · context
    A library of all possible 31 backbone N-methylated derivatives has been synthesized and tested for binding and activation at melanocortin receptor subtypes 1, 3, 4, and 5.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

  2. 02LabNot a test of Melanotan II aloneIn vitro (cell-free)Other

    The most potent derivative, N-methylated on four of five amide bonds, had a strongly preferred and less flexible backbone conformation in solution.

    In plain wordsIn lab tests, the most potent modified version of MT-II had a more fixed shape than related natural hormone analogues.

    Peptide
    Melanotan II
    Outcome
    Not applicableBackbone conformation of the most potent N-methylated derivative
    Study

    n: not reported in source

    Solution structure of the most potent derivative
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The most potent of these derivatives is N-methylated on four out of five amide bonds in the cyclic structure. Its solution structure indicates a strongly preferred backbone conformation that resembles other alpha-MSH analogs but possesses much less flexibility and in addition distinct differences in…

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.